Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Reviews in Endocrine and Metabolic Disorders
Erschienen in: Reviews in Endocrine and Metabolic Disorders 3/2016

23.06.2016

Neuroendocrinology of the skin

verfasst von: Theoharis C. Theoharides, Julia M. Stewart, Alexandra Taracanova, Pio Conti, Christos C. Zouboulis

Erschienen in: Reviews in Endocrine and Metabolic Disorders | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

The skin is considered the mirror of the soul and is affected by neurohormonal triggers, especially stress. Hair follicles, keratinocytes, mast cells, melanocytes, and sebocytes all express sex and stress hormones implicating them in a local “hypothalamic-pituitary-adrenal axis.” In particular, the peptides corticotropin-releasing hormone (CRH) and neurotensin (NT) have synergistic action stimulating mast cells and are uniquely elevated in the serum of patients with skin diseases exacerbated by stress. Addressing the neurohormonal regulation of skin function could lead to new targets for effective treatment of inflammatory skin diseases.
Literatur
1.
Al NF, Cox NH. Endocrinology and the skin. Br J Hosp Med (Lond). 2008;69(9):510–5.CrossRef
2.
Chang FC, Opp MR. IL-1 is a mediator of increases in slow-wave sleep induced by CRH receptor blockade. Am J Physiol Regul Integr Comp Physiol. 2000;279:R793–802.PubMed
3.
4.
Stuttgen G. Zentralnervensystem and Talgsekretion. Arch Klin Exp Dermatol. 2016;219:795–9.CrossRef
5.
Zouboulis CC, Seltmann H, Hiroi N, et al. Corticotropin-releasing hormone: an autocrine hormone that promotes lipogenesis in human sebocytes. Proc Natl Acad Sci U S A. 2002;99(10):7148–53.PubMedPubMedCentralCrossRef
6.
7.
Paus R, Theoharides TC, Arck PC. Neuroimmunoendocrine circuitry of the “brain-skin connection”. Trends Immunol. 2006;27(1):32–9.PubMedCrossRef
8.
9.
Slominski AT, Zmijewski MA, Zbytek B, Tobin DJ, Theoharides TC, Rivier J. Key role of CRF in the skin stress response system. Endocr Rev. 2013;34(6):827–84.PubMedPubMedCentralCrossRef
10.
Slominski A, Wortsman J, Luger T, Paus R, Solomon S. Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev. 2000;80:979–1020.PubMed
11.
Slominski AT, Zmijewski MA, Skobowiat C, Zbytek B, Slominski RM, Steketee JD. Sensing the environment: regulation of local and global homeostasis by the skin’s neuroendocrine system. Adv Anat Embryol Cell Biol. 2012;212:v. vii, 1-v, vii115.PubMedPubMedCentral
12.
Slominski A, Paus R, Mazurkiewicz J. Proopiomelanocortin expression in the skin during induced hair growth in mice. Experientia. 1992;48:50–4.PubMedCrossRef
13.
Slominski A, Mihm MC. Potential mechanism of skin response to stress. Int J Dermatol. 1996;35(12):849–51.PubMedCrossRef
14.
Slominski A. Identification of beta-endorphin, alpha-MSH and ACTH peptides in cultured human melanocytes, melanoma and squamous cell carcinoma cells by RP-HPLC. Exp Dermatol. 1998;7(4):213–6.PubMedCrossRef
15.
Slominski A, Paus R, Wortsman J. On the potential role of proopiomelanocortin in skin physiology and pathology. Mol Cell Endocrinol. 1993;93:C1–6.PubMedCrossRef
16.
Slominski A, Ermak G, Mazurkiewicz JE, Baker J, Wortsman J. Characterization of corticotropin-releasing hormone (CRH) in human skin. J Clin Endocrinol Metab. 1998;83:1020–4.PubMed
17.
Slominski A, Ermak G, Hwang J, Chakraborty A, Mazurkiewicz JE, Mihm M. Proopiomelanocortin, corticotropin releasing hormone and corticotropin releasing hormone receptor genes are expressed in human skin. FEBS Lett. 1995;374:113–6.PubMedCrossRef
18.
Slominski A, Zbytek B, Szczesniewski A, et al. CRH stimulation of corticosteroids production in melanocytes is mediated by ACTH. Am J Physiol Endocrinol Metab. 2005;288(4):E701–6.PubMedCrossRef
19.
Slominski A, Zbytek B, Semak I, Sweatman T, Wortsman J. CRH stimulates POMC activity and corticosterone production in dermal fibroblasts. J Neuroimmunol. 2005;162(1-2):97–102.PubMedCrossRef
20.
Slominski AT, Roloff B, Zbytek B, et al. Corticotropin releasing hormone and related peptides can act as bioregulatory factors in human keratinocytes. In Vitro Cell Dev Biol Anim. 2000;36:211–6.PubMedCrossRef
21.
Slominski A, Zbytek B, Pisarchik A, Slominski RM, Zmijewski MA. CRH functions as a growth factor/cytokine in the skin. J Cell Physiol. 2006;206(3):780–91.PubMedPubMedCentralCrossRef
22.
Slominski A, Wortsman J, Kohn L, et al. Expression of hypothalamic-pituitary-thyroid axis related genes in the human skin. J Invest Dermatol. 2002;119:1449–55.PubMedPubMedCentralCrossRef
23.
Slominski A, Wortsman J, Linton E, Pisarchik A, Zbytek B. The skin as a model for the immunodulatory effects of corticotropin-releasing hormone. In: Schaffer M, Stein C, editors. Mind over matter-regulation of peripheral inflammation by the CNS. Basel: Birkahauser Verlag; 2003. p. 149–76.CrossRef
24.
Paus R, Langan EA, Vidali S, Ramot Y, Andersen B. Neuroendocrinology of the hair follicle: principles and clinical perspectives. Trends Mol Med. 2014;20(10):559–70.PubMedCrossRef
25.
Roloff B, Fechner K, Slominski A, et al. Hair cycle-dependent expression of corticotropin-releasing factor (CRF) and CRF receptors in murine skin. FASEB J. 1998;12:287–97.PubMed
26.
Donelan J, Marchand J, Kempuraj D, Papadopoulou N, Theoharides TC. Perifollicular and perivascular mouse skin mast cells express corticotropin-releasing hormone receptor. J Inv Dermatol. 2006;126:929–32.CrossRef
27.
Ito N, Sugawara K, Bodo E, et al. Corticotropin-releasing hormone stimulates the in situ generation of mast cells from precursors in the human hair follicle mesenchyme. J Invest Dermatol. 2010;130(4):995–1004.PubMedCrossRef
28.
Ito N, Ito T, Kromminga A, et al. Human hair follicles display a functional equivalent of the hypothalamic-pituitary-adrenal axis and synthesize cortisol. FASEB J. 2005;19(10):1332–4.PubMed
29.
Gensure RC. Parathyroid hormone-related peptide and the hair cycle—is it the agonists or the antagonists that cause hair growth? Exp Dermatol. 2014;23(12):865–7.PubMedCrossRef
30.
Tsakalos ND, Theoharides TC, Kops SK, Askenase PW. Induction of mast cell secretion by parathormone. Biochem Pharmacol. 1983;32:355–60.PubMedCrossRef
31.
Alesci S, Bornstein SR. Neuroimmunoregulation of androgens in the adrenal gland and the skin. Horm Res. 2000;54(5-6):281–6.PubMed
32.
33.
Zouboulis CC, Bohm M. Neuroendocrine regulation of sebocytes—a pathogenetic link between stress and acne. Exp Dermatol. 2004;13 Suppl 4:31–5.PubMedCrossRef
34.
Elewa RM, Abdallah M, Youssef N, Zouboulis CC. Aging-related changes in cutaneous corticotropin-releasing hormone system reflect a defective neuroendocrine-stress response in aging. Rejuvenation Res. 2012;15(4):366–73.PubMedCrossRef
35.
Kono M, Nagata H, Umemura S, Kawana S, Osamura RY. In situ expression of corticotropin-releasing hormone (CRH) and proopiomelanocortin (POMC) genes in human skin. FASEB J. 2001;15(12):2297–9.PubMed
36.
Ganceviciene R, Bohm M, Fimmel S, Zouboulis CC. The role of neuropeptides in the multifactorial pathogenesis of acne vulgaris. Dermatoendocrinol. 2009;1(3):170–6.PubMedPubMedCentralCrossRef
37.
38.
Slominski A, Zbytek B, Nikolakis G, et al. Steroidogenesis in the skin: implications for local immune functions. J Steroid Biochem Mol Biol. 2013;137:107–23.PubMedPubMedCentralCrossRef
39.
Ganceviciene R, Graziene V, Fimmel S, Zouboulis CC. Involvement of the corticotropin-releasing hormone system in the pathogenesis of acne vulgaris. Br J Dermatol. 2009;160(2):345–52.PubMedCrossRef
40.
Ganceviciene R, Graziene V, Bohm M, Zouboulis CC. Increased in situ expression of melanocortin-1 receptor in sebaceous glands of lesional skin of patients with acne vulgaris. Exp Dermatol. 2007;16(7):547–52.PubMedCrossRef
41.
Bohm M, Schiller M, Stander S, et al. Evidence for expression of melanocortin-1 receptor in human sebocytes in vitro and in situ. J Invest Dermatol. 2002;118(3):533–9.PubMedCrossRef
42.
Zhang L, Li WH, Anthonavage M, Eisinger M. Melanocortin-5 receptor: a marker of human sebocyte differentiation. Peptides. 2006;27(2):413–20.PubMedCrossRef
43.
Bohm M, Li Z, Ottaviani M, et al. Beta-endorphin modulates lipogenesis in human sebocytes. J Invest Dermatol. 2004;123:A10.
44.
Stander S, Schmeltz M, Metze D, Luger T, Rulwied R. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci. 2005;38:177–88.PubMedCrossRef
45.
Theoharides TC, Cochrane DE. Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol. 2004;146(1-2):1–12.PubMedCrossRef
46.
Al’Abadie MS, Kent GG, Gawkrodger DJ. The relationship between stress and the onset and exacerbation of psoriasis and other skin conditions. Br J Dermatol. 1994;130(2):199–203.PubMedCrossRef
47.
Katsarou-Katsari A, Filippou A, Theoharides TC. Stress and inflammatory dermatoses. Int J Immunopathol Pharmacol. 1999;12:7–11.PubMed
48.
Griesemer RD. Emotionally triggered disease in a dermatologic practice. Phychiatr. 1978;8:407–12.
49.
Graham DT, Wolf S. The relation of eczema to attitude and to vascular reactions of the human skin. J Lab Clin Med. 1953;42(2):238–54.PubMed
50.
Linnet J, Jemec GB. Anxiety level and severity of skin condition predicts outcome of psychotherapy in atopic dermatitis patients. Int J Dermatol. 2001;40(10):632–6.PubMedCrossRef
51.
Seiffert K, Hilbert E, Schaechinger H, Zouboulis CC, Deter HC. Psychophysiological reactivity under mental stress in atopic dermatitis. Dermatology. 2005;210(4):286–93.PubMedCrossRef
52.
Stauder A, Kovacs M. Anxiety symptoms in allergic patients: identification and risk factors. Psychosom Med. 2003;65(5):816–23.PubMedCrossRef
53.
Sugiura H, Uehara M. Mitosis of mast cells in skin lesions of atopic dermatitis. Acta Derm Venereol (Stockh). 1993;73(4):296–9.
54.
Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis—part I: clinical and pathologic concepts. J Allergy Clin Immunol. 2011;127(5):1110–8.PubMedCrossRef
55.
Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis—part II: immune cell subsets and therapeutic concepts. J Allergy Clin Immunol. 2011;127(6):1420–32.PubMedCrossRef
56.
Slominski A. On the role of the corticotropin-releasing hormone signalling system in the aetiology of inflammatory skin disorders. Br J Dermatol. 2009;160(2):229–32.PubMedPubMedCentralCrossRef
57.
Albanesi C. Keratinocytes in allergic skin diseases. Curr Opin Allergy Clin Immunol. 2010;10(5):452–6.PubMedCrossRef
58.
Rahman S, Collins M, Williams CM, Ma HL. The pathology and immunology of atopic dermatitis. Inflamm Allergy Drug Targets. 2011;10(6):486–96.PubMedCrossRef
59.
Stander S, Steinhoff M. Pathophysiology of pruritus in atopic dermatitis: an overview. Exp Dermatol. 2002;11:12–24.PubMedCrossRef
60.
Stander S, Luger TA. Itch in atopic dermatitis—pathophysiology and treatment. Acta Dermatovenerol Croat. 2010;18(4):289–96.PubMed
61.
Bonness S, Bieber T. Molecular basis of atopic dermatitis. Curr Opin Allergy Clin Immunol. 2007;7(5):382–6.PubMedCrossRef
62.
Harvima IT, Nilsson G, Suttle MM, Naukkarinen A. Is there a role for mast cells in psoriasis? Arch Dermatol Res. 2008;300(9):461–76.PubMedCrossRef
63.
Naukkarinen A, Jarvikallio A, Lakkakorpi J, Harvima IT, Harvima RJ, Horsmanheimo M. Quantitative histochemical analysis of mast cells and sensory nerves in psoriatic skin. J Pathol. 1996;180:200–5.PubMedCrossRef
64.
Jiang WY, Chattedee AD, Raychaudhuri SP, Raychaudhuri SK, Farber EM. Mast cell density and IL-8 expression in nonlesional and lesional psoriatic skin. Int J Dermatol. 2001;40(11):699–703.PubMedCrossRef
65.
Harvima IT, Viinamäki H, Naukkarinen A, Paukkonen K, Neittaanmäki H, Horsmanheimo M. Association of cutaneous mast cells and sensory nerves with psychic stress in psoriasis. Psychother Psychosom. 1993;60:168–76.PubMedCrossRef
66.
Groneberg DA, Bester C, Grutzkau A, et al. Mast cells and vasculature in atopic dermatitis—potential stimulus of neoangiogenesis. Allergy. 2005;60(1):90–7.PubMedCrossRef
67.
Damsgaard TE, Olesen AB, Srensen FB. Thestrup-Pedersen K, Schitz PO. Mast cells and atopic dermatitis. Stereological quantification of mast cells in atopic dermatitis and normal human skin. Arch Dermatol Res. 1997;289(5):256–60.PubMedCrossRef
68.
Sugiura H, Hirota Y, Uehara M. Heterogeneous distribution of mast cells in lichenified lesions of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1989;144:115–8.
69.
Remröd C, Lonne-Rahm S, Nordliond K. Study of substance P and its receptor neurokinin-1 in psoriasis and their relation to chronic stress and pruritus. Arch Dermatol Res. 2007;299:85–91.PubMedCrossRef
70.
Jarvikallio A, Harvima IT, Naukkarinen A. Mast cells, nerves and neuropeptides in atopic dermatitis and nummular eczema. Arch Dermatol Res. 2003;295(1):2–7.PubMed
71.
Christy AL, Brown MA. The multitasking mast cell: positive and negative roles in the progression of autoimmunity. J Immunol. 2007;179(5):2673–9.PubMedCrossRef
72.
Theoharides TC, Zhang B, Kempuraj D, et al. IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc Natl Acad Sci U S A. 2010;107(9):4448–53.PubMedPubMedCentralCrossRef
73.
Rozniecki JJ, Dimitriadou V, Lambracht-Hall M, Pang X, Theoharides TC. Morphological and functional demonstration of rat dura mast cell-neuron interactions in vitro and in vivo. Brain Res. 1999;849:1–15.PubMedCrossRef
74.
Theoharides TC, Singh LK, Boucher W, et al. Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its pro-inflammatory effects. Endocrinology. 1998;139:403–13.PubMed
75.
Crompton R, Clifton VL, Bisits AT, Read MA, Smith R, Wright IM. Corticotropin-releasing hormone causes vasodilation in human skin via mast cell-dependent pathways. J Clin Endocrinol Metab. 2003;88:5427–32.PubMedCrossRef
76.
Cao J, Papadopoulou N, Kempuraj D, et al. Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. J Immunol. 2005;174(12):7665–75.PubMedCrossRef
77.
Slominski A, Wortsman J. Neuroendocrinology of the skin. Endocr Rev. 2000;21:457–87.PubMed
78.
Cao J, Boucher W, Donelan JM, Theoharides TC. Acute stress and intravesical corticotropin-releasing hormone induces mast cell-dependent vascular endothelial growth factor release from mouse bladder explants. J Urol. 2006;176:1208–13.PubMedCrossRef
79.
Kandere-Grzybowska K, Gheorghe D, Priller J, et al. Stress-induced dura vascular permeability does not develop in mast cell-deficient and neurokinin-1 receptor knockout mice. Brain Res. 2003;980:213–20.PubMedCrossRef
80.
Ercan F, San T, Cavdar S. The effects of cold-restraint stress on urinary bladder wall compared with interstitial cystitis morphology. Urol Res. 1999;27:454–61.PubMedCrossRef
81.
Spanos C, Pang X, Ligris K, et al. Stress-induced bladder mast cell activation: implications for interstitial cystitis. J Urol. 1997;157:669–72.PubMedCrossRef
82.
Theoharides TC, Sant GR. Neuroimmune connections and regulation of function in the urinary bladder. In: Bienenstock J, Goetzl E, Blennerhassett M, editors. Autonomic neuroimmunology. Lausanne: Hardwood Academic Publishers; 2003. p. 345–69.CrossRef
83.
Kaneko K, Kawana S, Arai K, Shibasaki T. Corticotropin-releasing factor receptor type 1 is involved in the stress-induced exacerbation of chronic contact dermatitis in rats. Exp Dermatol. 2003;12:47–52.PubMedCrossRef
84.
Theoharides TC, Donelan JM, Papadopoulou N, Cao J, Kempuraj D, Conti P. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci. 2004;25(11):563–8.PubMedCrossRef
85.
O’Kane M, Murphy EP, Kirby B. The role of corticotropin-releasing hormone in immune-mediated cutaneous inflammatory disease. Exp Dermatol. 2006;15(3):143–53.PubMedCrossRef
86.
Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med. 1995;332:1351–62.PubMedCrossRef
87.
88.
Slominski A, Wortsman J, Pisarchik A, et al. Cutaneous expression of corticotropin-releasing hormone (CRH), urocortin, and CRH receptors. FASEB J. 2001;15:1678–93.PubMedCrossRef
89.
Karalis K, Louis JM, Bae D, Hilderbrand H, Majzoub JA. CRH and the immune system. J Neuroimmunol. 1997;72:131–6.PubMedCrossRef
90.
Kempuraj D, Papadopoulou NG, Lytinas M, et al. Corticotropin-releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells. Endocrinology. 2004;145:43–8.PubMedCrossRef
91.
Bossi F, Frossi B, Radillo O, et al. Mast cells are critically involved in serum-mediated vascular leakage in chronic urticaria beyond high-affinity IgE receptor stimulation. Allergy. 2011;66:1538–45.PubMedCrossRef
92.
Lytinas M, Kempuraj D, Huang M, Boucher W, Esposito P, Theoharides TC. Acute stress results in skin corticotropin-releasing hormone secretion, mast cell activation and vascular permeability, an effect mimicked by intradermal corticotropin-releasing hormone and inhibited by histamine-1 receptor antagonists. Int Arch Allergy Immunol. 2003;130:224–31.PubMedCrossRef
93.
Donelan J, Boucher W, Papadopoulou N, Lytinas M, Papaliodis D, Theoharides TC. Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process. Proc Natl Acad Sci U S A. 2006;103:7759–64.PubMedPubMedCentralCrossRef
94.
Buske-Kirschbaum A, Ebrecht M, Kern S, Gierens A, Hellhammer DH. Personality characteristics in chronic and non-chronic allergic conditions. Brain Behav Immun. 2008;22(5):762–8.PubMedCrossRef
95.
Theoharides TC, Kempuraj D, Marchand J, et al. Urticaria pigmentosa associated with acute stress and lesional skin mast cell expression of CRF-R1. Clin Exp Dermatol. 2008;34:e163–6.PubMedCrossRef
96.
Theoharides TC, Petra AI, Stewart JM, Tsilioni I, Panagiotidou S, Akin C. High serum corticotropin-releasing hormone (CRH) and bone marrow mast cell CRH receptor expression in a mastocytosis patient. J Allergy Clin Immunol. 2014;134(5):1197–9.PubMedCrossRef
97.
Liu FT, Goodarzi H, Chen HY. IgE, Mast cells, and eosinophils in atopic dermatitis. Clin Rev Allergy Immunol. 2011;41:298–310.PubMedCrossRef
98.
Bachelet I, Levi-Schaffer F, Mekori YA. Mast cells: not only in allergy. Immunol Allergy Clin North Am. 2006;26(3):407–25.PubMedCrossRef
99.
Galli SJ, Tsai M. Mast cells in allergy and infection: versatile effector and regulatory cells in innate and adaptive immunity. Eur J Immunol. 2010;40(7):1843–51.PubMedPubMedCentralCrossRef
100.
Theoharides TC, Valent P, Akin C. Mast cells, mastocytosis, and related disorders. N Engl J Med. 2015;373(2):163–72.PubMedCrossRef
101.
Galli SJ, Grimbaldeston M, Tsai M. Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol. 2008;8(6):478–86.PubMedPubMedCentralCrossRef
102.
Galli SJ, Nakae S, Tsai M. Mast cells in the development of adaptive immune responses. Nat Immunol. 2005;6(2):135–42.PubMedCrossRef
103.
Galli SJ, Tsai M. Mast cells: versatile regulators of inflammation, tissue remodeling, host defense and homeostasis. J Dermatol Sci. 2008;49(1):7–19.PubMedCrossRef
104.
Theoharides TC, Kalogeromitros D. The critical role of mast cell in allergy and inflammation. Ann NY Acad Sci. 2006;1088:78–99.PubMedCrossRef
105.
Cao J, Curtis CL, Theoharides TC. Corticotropin-releasing hormone induces vascular endothelial growth factor release from human mast cells via the cAMP/protein kinase A/p38 mitogen-activated protein kinase pathway. Mol Pharmacol. 2006;69(3):998–1006.PubMed
106.
Artuc M, Hermes B, Steckelings UM, Grutzkau A, Henz BM. Mast cells and their mediators in cutaneous wound healing—active participants or innocent bystanders? Exp Dermatol. 1999;8:1–16.PubMedCrossRef
107.
Puxeddu I, Ribatti D, Crivellato E, Levi-Schaffer F. Mast cells and eosinophils: a novel link between inflammation and angiogenesis in allergic diseases. J Allergy Clin Immunol. 2005;116(3):531–6.PubMedCrossRef
108.
Brown JM, Wilson TM, Metcalfe DD. The mast cell and allergic diseases: role in pathogenesis and implications for therapy. Clin Exp Allergy. 2008;38(1):4–18.PubMed
109.
Gordon JR, Galli SJ. Mast cells as a source of both preformed and immunologically inducible TNF-a/cachectin. Nature. 1990;346(6281):274–6.PubMedCrossRef
110.
Olszewski MB, Groot AJ, Dastych J, Knol EF. TNF trafficking to human mast cell granules: mature chain-dependent endocytosis. J Immunol. 2007;178(9):5701–9.PubMedCrossRef
111.
112.
113.
Zhang B, Alysandratos KD, Angelidou A, et al. Human mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: relevance to atopic dermatitis. J Allergy Clin Immunol. 2011;127(6):1522–31.PubMedPubMedCentralCrossRef
114.
Kritas SK, Caraffa A, Antinolfi P, et al. Nerve growth factor interactions with mast cells. Int J Immunopathol Pharmacol. 2014;27(1):15–9.PubMed
115.
Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’? PLoS One. 2008;3(10):e3331.PubMedPubMedCentralCrossRef
116.
Enoksson M, Lyberg K, Moller-Westerberg C, Fallon PG, Nilsson G, Lunderius-Andersson C. Mast cells as sensors of cell injury through IL-33 recognition. J Immunol. 2011;186(4):2523–8.PubMedCrossRef
117.
Chakraborty S, Kaushik DK, Gupta M, Basu A. Inflammasome signaling at the heart of central nervous system pathology. J Neurosci Res. 2010;88(8):1615–31.PubMed
118.
Mustain WC, Rychahou PG, Evers BM. The role of neurotensin in physiologic and pathologic processes. Curr Opin Endocrinol Diabetes Obes. 2011;18(1):75–82.PubMedCrossRef
119.
Feldberg RS, Cochrane DE, Carraway RE, et al. Evidence for a neurotensin receptor in rat serosal mast cells. Inflamm Res. 1998;47:245–50.PubMedCrossRef
120.
Barrocas AM, Cochrane DE, Carraway RE, Feldberg RS. Neurotensin stimulation of mast cell secretion is receptor-mediated, pertussis-toxin sensitive and requires activation of phospholipase C. Immunopharmacology. 1999;41:131–7.PubMedCrossRef
121.
Carraway R, Cochrane DE, Lansman JB, Leeman SE, Paterson BM, Welch HJ. Neurotensin stimulates exocytotic histamine secretion from rat mast cells and elevates plasma histamine levels. J Physiol. 1982;323:403–14.PubMedPubMedCentralCrossRef
122.
Cochrane DE, Emigh C, Levine G, Carraway RE, Leeman SE. Neurotensin alters cutaneous vascular permeability and stimulates histamine release from isolated skin. Ann NY Acad Sci. 1982;400:396–7.CrossRef
123.
Cochrane DE, Boucher W, Bibb P. Neurotensin stimulates histamine release in in vivo skin ‘blisters’ in rats: an effect inhibited by cromolyn or somatostatin. Int Arch Allergy Appl Immunol. 1986;80:225–30.PubMedCrossRef
124.
Singh LK, Pang X, Alexacos N, Letourneau R, Theoharides TC. Acute immobilization stress triggers skin mast cell degranulation via corticotropin-releasing hormone, neurotensin and substance P: a link to neurogenic skin disorders. Brain Behav Immun. 1999;13:225–39.PubMedCrossRef
125.
Cochrane DE, Carraway RE, Boucher W, Feldberg RS. Rapid degradation of neutotensin by stimulated rat mast cells. Peptides. 1991;12:1187–94.PubMedCrossRef
126.
Maurer M, Wedemeyer J, Metz M, et al. Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. Nature. 2004;432:512–6.PubMedCrossRef
127.
Zhang B, Asadi S, Weng Z, Sismanopoulos N, Theoharides TC. Stimulated human mast cells secrete mitochondrial components that have autocrine and paracrine inflammatory actions. PLoS One. 2012;7(12):e49767.PubMedPubMedCentralCrossRef
128.
Asadi S, Theoharides TC. Corticotropin-releasing hormone and extracellular mitochondria augment IgE-stimulated human mast-cell vascular endothelial growth factor release, which is inhibited by luteolin. J Neuroinflam. 2012;9(1):85.CrossRef
129.
130.
Matsumoto I, Inoue Y, Shimada T, Aikawa T. Brain mast cells act as an immune gate to the hypothalamic-pituitary-adrenal axis in dogs. J Exp Med. 2001;194:71–8.PubMedPubMedCentralCrossRef
131.
Bugajski AJ, Chlap Z, Gadek-Michalska A, Borycz J, Bugajski J. Degranulation and decrease in histamine levels of thalamic mast cells coincides with corticosterone secretion induced by compound 48/80. Inflamm Res. 1995;44 Suppl 1:S50–1.PubMedCrossRef
132.
Kalogeromitros D, Syrigou EI, Makris M, et al. Nasal provocation of patients with allergic rhinitis and the hypothalamic-pituitary-adrenal axis. Ann Allergy, Asthma, Immunol. 2007;98:269–73.CrossRef
133.
Malki A, Fiedler J, Fricke K, Ballweg I, Pfaffl MW, Krautwurst D. Class I odorant receptors, TAS1R and TAS2R taste receptors, are markers for subpopulations of circulating leukocytes. J Leukoc Biol. 2015;97(3):533–45.PubMedCrossRef
134.
Catini C, Legnaioli M. Role of mast cells in health: daily rhythmic variations in their number, exocytotic activity, histamine and serotonin content in the rat thyroid gland. Eur J Histochem. 1992;36(4):501–16.PubMed
135.
Molyva D, Kalokasidis K, Poulios C, et al. Rupatadine effectively prevents the histamine-induced up regulation of histamine H1R and bradykinin B2R receptor gene expression in the rat paw. Pharmacol Rep. 2014;66(6):952–5.PubMedCrossRef
136.
Nakao A, Nakamura Y, Shibata S. The circadian clock functions as a potent regulator of allergic reaction. Allergy. 2015;70(5):467–73.PubMedCrossRef
137.
Maldonado MD, Mora-Santos M, Naji L, Carrascosa-Salmoral MP, Naranjo MC, Calvo JR. Evidence of melatonin synthesis and release by mast cells. Possible modulatory role on inflammation. Pharmacol Res. 2010;62(3):282–7.PubMedCrossRef
138.
Metz M, Maurer M. Innate immunity and allergy in the skin. Curr Opin Immunol. 2009;21(6):687–93.PubMedCrossRef
139.
Metz M, Maurer M. Mast cells--key effector cells in immune responses. Trends Immunol. 2007;28(5):234–41.PubMedCrossRef
140.
141.
Theoharides TC. Mast cell: a neuroimmunoendocrine master player. Int J Tissue React. 1996;18(1):1–21.PubMed
142.
Metz M, Grimbaldeston MA, Nakae S, Piliponsky AM, Tsai M, Galli SJ. Mast cells in the promotion and limitation of chronic inflammation. Immunol Rev. 2007;217:304–28.PubMedCrossRef
143.
Theoharides TC, Alysandratos KD, Angelidou A, et al. Mast cells and inflammation. Biochim Biophys Acta. 2012;1822(1):21–33.PubMedCrossRef
144.
Greene LW, Asadipooya K, Corradi PF, Akin C. Endocrine manifestations of systemic mastocytosis in bone. Rev Endocr Metab Disord. 2016. May 30.
145.
Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol. 2011;29:415–45.PubMedCrossRef
146.
Nati M, Haddad D, Birkenfeld AL, Koch CA, Chavakis T, Chatzigeorgiou A. The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH). Rev Endocr Metab Disord. 2016;17(1):29–39.PubMedCrossRef
147.
Klöting N, Blüher M. Adipocyte dysfunction, inflammation and metabolic syndrome. Rev Endocr Metab Disord. 2014;15(4):277–87.PubMedCrossRef
148.
Kammoun HL, Kraakman MJ, Febbraio MA. Adipose tissue inflammation in glucose metabolism. Rev Endocr Metab Disord. 2014;15(1):31–44.PubMedCrossRef
149.
150.
Taildeman J, Perez-Novo CA, Rottiers I, et al. Human mast cells express leptin and leptin receptors. Histochem Cell Biol. 2009;131(6):703–11.PubMedCrossRef
151.
Theoharides TC, Sismanopoulos N, Delivanis DA, Zhang B, Hatziagelaki EE, Kalogeromitros D. Mast cells squeeze the heart and stretch the gird: their role in atherosclerosis and obesity. Trends Pharmacol Sci. 2011;32(9):534–42.PubMedCrossRef
152.
Liu J, Divoux A, Sun J, et al. Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med. 2009;15(8):940–5.PubMedPubMedCentralCrossRef
153.
Zhou Y, Yu X, Chen H, et al. Leptin deficiency shifts mast cells toward anti-Inflammatory actions and protects mice from obesity and diabetes by polarizing M2 macrophages. Cell Metab. 2015;22(6):1045–58.PubMedPubMedCentralCrossRef
154.
Eyster KM. The estrogen receptors: an overview from different perspectives. Methods Mol Biol. 2016;1366:1–10.PubMedCrossRef
155.
Raghunath RS, Venables ZC, Millington GW. The menstrual cycle and the skin. Clin Exp Dermatol. 2015;40(2):111–5.PubMedCrossRef
156.
157.
Janik ME, Belkot K, Przybylo M. Is oestrogen an important player in melanoma progression? Contemp Oncol (Pozn). 2014;18(5):302–6.
158.
Bizzarri C, Bottaro G. Endocrine implications of neurofibromatosis 1 in childhood. Horm Res Paediatr. 2015;83(4):232–41.PubMedCrossRef
159.
Jabbour SA. Skin manifestations of hormone-secreting tumors. Dermatol Ther. 2010;23(6):643–50.PubMedCrossRef
160.
Kanaka-Gantenbein C, Kogia C, Abdel-Naser MB, Chrousos GP. Skin manifestations of growth hormone-induced diseases. Rev Endocr Metab Disord. 2016; in press
161.
Zaitsu M, Narita S, Lambert KC, et al. Estradiol activates mast cells via a non-genomic estrogen receptor-alpha and calcium influx. Mol Immunol. 2007;44(8):1977–85.PubMedCrossRef
162.
Narita S, Goldblum RM, Watson CS, et al. Environmental estrogens induce mast cell degranulation and enhance IgE-mediated release of allergic mediators. Environ Health Perspect. 2007;115(1):48–52.PubMedCrossRef
163.
Alevizos M, Karagkouni A, Kontou-Fili K, Theoharides TC. A probable case report of stress-induced anaphylaxis. Ann Allergy Asthma Immunol. 2014;112(4):383–4.PubMedCrossRef
164.
Jensen F, Woudwyk M, Teles A, et al. Estradiol and progesterone regulate the migration of mast cells from the periphery to the uterus and induce their maturation and degranulation. PLoS One. 2010;5(12):e14409.PubMedPubMedCentralCrossRef
165.
Jaiswal K, Krishna A. Effects of hormones on the number, distribution and degranulation of mast cells in the ovarian complex of mice. Acta Physiol Hung. 1996;84(2):183–90.PubMed
166.
Theoharides TC, Pang X, Letourneau R, Sant GR. Interstitial cystitis: a neuroimmunoendocrine disorder. Ann NY Acad Sci. 1998;840:619–34.PubMedCrossRef
167.
Spanos C, El-Mansoury M, Letourneau RJ, et al. Carbachol-induced activation of bladder mast cells is augmented by estradiol—implications for interstitial cystitis. Urology. 1996;48:809–16.PubMedCrossRef
168.
Pang X, Cotreau-Bibbo MM, Sant GR, Theoharides TC. Bladder mast cell expression of high affinity estrogen receptors in patients with interstitial cystitis. Br J Urol. 1995;75:154–61.PubMedCrossRef
169.
Hox V, Desai A, Bandara G, Gilfillan AM, Metcalfe DD, Olivera A. Estrogen increases the severity of anaphylaxis in female mice through enhanced endothelial nitric oxide synthase expression and nitric oxide production. J Allergy Clin Immunol. 2015;135(3):729–36.PubMedCrossRef
170.
Zhao XJ, McKerr G, Dong Z, et al. Expression of oestrogen and progesterone receptors by mast cells alone, but not lymphocytes, macrophages or other immune cells in human upper airways. Thorax. 2001;56(3):205–11.PubMedPubMedCentralCrossRef
171.
Vasiadi M, Kempuraj D, Boucher W, Kalogeromitros D, Theoharides TC. Progesterone inhibits mast cell secretion. Int J Immunopath Pharmacol. 2006;19:787–94.
172.
Vliagoftis H, Dimitriadou V, Theoharides TC. Progesterone triggers selective mast cell secretion of 5-hydroxytryptamine. Int Arch Allergy Appl Immunol. 1990;93(2-3):113–9.PubMedCrossRef
173.
Guhl S, Artuc M, Zuberbier T, Babina M. Testosterone exerts selective anti-inflammatory effects on human skin mast cells in a cell subset dependent manner. Exp Dermatol. 2012;21(11):878–80.PubMedCrossRef
174.
Kriegsfeld LJ, Hotchkiss AK, Demas GE, Silverman AJ, Silver R, Nelson RJ. Brain mast cells are influenced by chemosensory cues associated with estrus induction in female prairie voles (Microtus ochrogaster). Horm Behav. 2003;44(5):377–84.PubMedPubMedCentralCrossRef
175.
Silverman AJ, Millar RP, King JA, Zhuang X, Silver R. Mast cells containing gonadotropin-releasing hormone-like immunoreactivity in the brain of doves. Proc Natl Acad Sci U S A. 1994;91:3675–99.CrossRef
176.
Silver R, Ramos CL, Silverman AJ. Sexual behavior triggers the appearance of non-neuronal cells containing gonadotropin-releasing hormone-like immunoreactivity. J Neuroendocrinol. 1991;4:1–3.
177.
Aydin Y, Tuncel N, Gurer F, Tuncel M, Kosar M, Oflaz G. Ovarian, uterine and brain mast cells in female rats: cyclic changes and contribution to tissue histamine. Comp Biochem Physiol A Mol Integr Physiol. 1998;120(2):255–62.PubMedCrossRef
178.
Rudolph MI, Oviedo C, Vega E, et al. Oxytocin inhibits the uptake of serotonin into uterine mast cells. J Pharmacol Exp Ther. 1998;287(1):389–94.PubMed
179.
Hillhouse EW, Grammatopoulos DK. Role of stress peptides during human pregnancy and labour. Reproduction. 2002;124:323–9.PubMedCrossRef
180.
Reis FM, Petraglia F. The placenta as a neuroendocrine organ. Front Horm Res. 2001;27:216–28.PubMedCrossRef
181.
Lockwood CJ. Stress-associated preterm delivery: the role of corticotropin-releasing hormone. Am J Obstet Gynecol. 1999;180:S264–266.PubMedCrossRef
182.
Madhappan B, Kempuraj D, Christodoulou S, et al. High levels of intrauterine corticotropin-releasing hormone, urocortin, tryptase and IL-8 in spontaneous abortions. Endocrinology. 2003;144:2285–90.PubMedCrossRef
183.
Arck PC, Rose M, Hertwig K, Hagen E, Hildebrandt M, Klapp BF. Stress and immune mediators in miscarriage. Hum Reprod. 2001;16:1505–11.PubMedCrossRef
184.
Marx L, Arck P, Kieslich C, Mitterlechner S, Kapp M, Dietl J. Decidual mast cells might be involved in the onset of human first-trimester abortion. Am J Reprod Immunol. 1999;41:34–40.PubMedCrossRef
185.
Kempuraj D, Papadopoulou N, Stanford EJ, et al. Increased numbers of activated mast cells in endometriosis lesions positive for corticotropin-releasing hormone (CRH) and urocortin. Am J Reprod Immunol. 2004;52:267–75.PubMedCrossRef
186.
Cuevas M, Flores I, Thompson KJ, Ramos-Ortolaza DL, Torres-Reveron A, Appleyard CB. Stress exacerbates endometriosis manifestations and inflammatory parameters in an animal model. Reprod Sci. 2012;19(8):851–62.PubMedPubMedCentralCrossRef
Metadaten
Titel
Neuroendocrinology of the skin
verfasst von
Theoharis C. Theoharides
Julia M. Stewart
Alexandra Taracanova
Pio Conti
Christos C. Zouboulis
Publikationsdatum
23.06.2016
Verlag
Springer US
Erschienen in
Reviews in Endocrine and Metabolic Disorders / Ausgabe 3/2016
Print ISSN: 1389-9155
Elektronische ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-016-9369-9

Weitere Artikel der Ausgabe 3/2016

Reviews in Endocrine and Metabolic Disorders 3/2016 Zur Ausgabe

ReviewPaper

Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa

ReviewPaper

Flushing in (neuro)endocrinology

ReviewPaper

Skin steroidogenesis in health and disease

ReviewPaper

Hereditary syndromes predisposing to endocrine tumors and their skin manifestations

ReviewPaper

Male fertility and skin diseases

ReviewPaper

Stress-related skin disorders

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise